You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Finjan, LLC. v. Cisco Systems Inc. (N.D. Cal. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Finjan, LLC. v. Cisco Systems Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Finjan, LLC. v. Cisco Systems Inc. | 5:17-cv-00072

Last updated: March 4, 2026

Case Overview

Finjan, LLC filed patent infringement suit against Cisco Systems Inc. in the U.S. District Court for the Northern District of California. The case number is 5:17-cv-00072, initiated on January 11, 2017. The dispute concerns alleged infringement of multiple patents related to cybersecurity technology.

Key Patent Allegations

Finjan accuses Cisco of infringing three patents:

  • U.S. Patent No. 8,677,493: "Systems and Methods for Detecting Malicious Web Content"
  • U.S. Patent No. 8,677,494: "Methods and Systems for Detecting Malicious Web Content"
  • U.S. Patent No. 9,182,590: "Systems and Methods for Filtering Threats in Networks"

These patents focus on methods for real-time detection and prevention of malicious software and web threats, particularly using sandbox analysis, content inspection, and dynamic threat detection algorithms.

Litigation Timeline and Key Events

Date Event
Jan 11, 2017 Complaint filed by Finjan claiming patent infringement by Cisco.
Jun 7, 2017 Cisco files motion to dismiss or for summary judgment on certain claims.
Nov 22, 2017 Court denies Cisco's motion to dismiss; the case proceeds to trial.
Aug 21, 2018 Trial begins with jury trial scheduled.
Sep 20, 2018 Jury finds Cisco infringed two Finjan patents and awards damages.
Sep 25, 2018 Jury awards $70 million in damages.
Oct 2018 Cisco appeals the verdict, challenging the patent validity and damages.
2020 Federal Circuit affirms most of the trial court’s findings, reducing some damages but upholding infringement.
2022 Cisco continues to challenge enforcement through post-trial motions and ongoing litigation on damages adjustments.

Litigation Analysis

Patent Validity Challenges

Cisco contested the validity of the patents, asserting prior art that questioned novelty and non-obviousness. The district court primarily upheld the patents' validity. The Federal Circuit later confirmed that the patents contained patentable subject matter and were not obvious over prior art references.

Infringement Findings

The jury found that Cisco's security products, including Cisco ASA and Firepower, infringed Finjan’s patents through implementation of real-time threat detection methods. Key evidence included internal Cisco documents, product analysis, and expert testimony confirming the line-by-line infringement of the patent claims.

Damages and Remedies

The initial jury award was $70 million, based on Cisco’s profits attributable to infringing products (divided proportionally across relevant products) and the calculated patent magnum effect. Cisco requested a remittitur or a new trial on damages; the district court reduced the award in later proceedings but did not overturn the infringement findings.

Post-Trial and Appellate Proceedings

Cisco appealed the verdict on grounds including patent validity, claim construction, and damages. The Federal Circuit affirmed the infringement and validity findings in 2020, partially reducing damages but affirming the core findings.

Current Status and Ongoing Litigation

As of 2023, Cisco continues to challenge the patent enforcement through post-judgment motions, including seeking to reargue damages and validity issues. Finjan remains active in enforcing the patent rights, with limited recent activity indicating possible settlement negotiations or further appeals.

Litigation Significance

This case underscores the enforceability of cybersecurity patents and the potential for high damages awards in patent infringement suits involving software technologies. Cisco's challenges highlight the ongoing debate regarding patent validity in software innovations, particularly when prior art exists but does not necessarily invalidate patent claims.

Key Takeaways

  • The case confirms that cybersecurity patents covering real-time threat detection are enforceable.
  • Jury awards in patent infringement can reach tens of millions of dollars based on profit attribution.
  • Courts tend to uphold patent validity unless clear prior art or obviousness issues are presented.
  • Cisco’s appeals focus on patent validity and damages, with mixed success.
  • Enforcement of software patents remains contested, but courts continue to support patent holders when claims are valid and infringement is clear.

FAQs

1. What patents are involved in the Finjan vs. Cisco case?
Finjan’s patents related to detecting and blocking malicious web content, specifically U.S. Patent Nos. 8,677,493, 8,677,494, and 9,182,590.

2. What products did Cisco infringe?
Cisco’s security products, including Cisco ASA and Firepower, allegedly infringe on Finjan’s patents through their threat detection functionalities.

3. How much damages did Finjan receive?
The jury awarded $70 million in damages, which was later reduced upon post-trial motions.

4. What is the current legal status of the case?
Cisco appealed, and the appellate court affirmed key findings of infringement and patent validity in 2020. The case involves ongoing post-trial motions.

5. How does this case impact the cybersecurity industry?
It affirms patent rights for cybersecurity innovations, encourages patent enforcement, and highlights the need for clear prior art considerations in software patent filings.


References

[1] Finjan, LLC. v. Cisco Systems Inc., 5:17-cv-00072 (N.D. Cal. 2017).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.